Familial polyposis coli: the management of desmoid tumor bleeding

All patients were alive and underwent follow-ups for 5 years post-surgery; only 1 patient with parietal localization showed a local relapse after 2 years.

Conclusions: We propose a modulated approach to the single patient with FAP, with surgery as treatment of choice for parietal localization disease and integrating different kinds of therapies (surgery alone or associated with RT, CT) for the intra-abdominal tumor.

Keywords: Desmoid tumor; Familial adenomatous polyposis; Radiotherapy; Surgery

1 Background

In 1838 Johannes Mueller first described a desmoid tumor (DT) as a neoplasia arising from tendons, band-like in shape, with local aggressiveness and possibility of recurrence [1]. Patients with familial adenomatous polyposis (FAP) may develop soft-tissue tumors, DTs. These tumors are considered benign but can be life threatening through progressive enlargement and consequently, pressure on gastrointestinal or urinary tracts, nervous or vascular systems.

DTs can arise in the mesentery, abdominal wall, or areas of scars; they are considered a benign entity but can cause severe morbidity and mortality because of their progressive growth that threatens the intra-abdominal organs, nerves, and vessels [2]. They occur in about 10% to 25% of FAP patients, commonly in women, and are one of the most important causes of death after colectomy [3].

FAP is an inherited syndrome that, with other similar neoplasms such as Lynch syndrome, MUTYH-associated polyposis (MAP), and several hamartomatous polyposis conditions, accounts for about 3% to 6% of all colorectal cancers [3-7]. The etiopathogenesis is still unknown, but there are
Management of desmoid tumor bleeding

2 Methods

We enrolled all the consecutive patients with FAP who underwent surgery at the Unit of General Surgery and Transplant, University of Naples Federico II and evaluated the incidence of DTs on FAP between years 1996 and 2016. All procedures applied were in accordance with international guidelines, with the standards of the local ethics committees, and with the Helsinki Declaration of 1975, 1983 revision. At the first appointment, each patient signed informed consent for the surgical procedure and collection and use in clinical research of the data obtained, as established by the Ethics Committee of AOU-University of Naples Federico II.

All patients at admission submitted to blood exams, ultrasound, CT Scan, and fine-needle cytology (FNC) in accordance with good clinical practice. The safety and the efficacy of surgical treatment were assessed. All patients were re-evaluated by periodic follow-ups, including examination by a physician, chest X-ray, and computed tomography abdominopelvic or magnetic resonance imaging every 3 months for the first year, every 6 months for the following 4 years, and subsequently every year.

3 Results

During the ten years 1996 to 2016 we observed 45 consecutive patients with FAP; of these 5 presented with both FAP and DT. These 5 patients were all female, aged between 25 and 65 years old, and underwent surgery in the previous 3 to 6 years for FAP: 1 underwent total colectomy combined with ileo-rectal anastomosis (IRA) and 4 received a proctocolectomy with ileal pouch-anal anastomosis (IPAA). The demographic and clinical characteristics of the 5 patients with FAP and DT are shown in Table 1. The desmoids were located in 2 patients who were members of the same family, at rectus abdominis; in 2 cases at the external oblique muscle, and at the mesentery in 1 patient. (Table 1)

The patients with parietal tumor showed no symptoms; they referred only to the onset of a movable and painless abdominal mass. One of the desmoids found in the external oblique muscle showed bleeding, but without anemia. The patient with the mesenteric desmoid reported abdominal pain, weight loss, and sub-occlusive crises, associated with left hydronephrosis.

Surgical treatment was possible in all parietal locations, in the form of wide exeresis. (Table 1, Figure 1). The patients were discharged 6 to 8 days after surgery without complications. The mesenteric desmoid was unresectable at laparotomy because of its connections with the great
abdominal vessels and small bowel loops. Therefore, the patient underwent TC-guided drainage and ureteral stenting to treat the left hydronephrosis and was treated with tamoxifen and sulindac.

One patient received post-operative radiotherapy, whereas the others followed an adjuvant therapy with sulindac and tamoxifen in the year after the operation. After 1 year of follow-up, the patient was alive and in good health, but the tumor had not regressed. Therefore, chemotherapy with doxorubicin plus dacarbazine was performed; she showed a partial response. At 3 years after the initial diagnosis, she is alive with a tumoral regression shown on CT scan and DMSA scintigraphy. (Table 2)

The DT represents an unfortunate event for patient with FAP and is the third most frequent cause of death in this patient setting. The management of DT is not yet standardized, and it can be different in case of parietal or intra-abdominal locations. Our experience shows how the treatment of these tumors might be particularly challenging. In patients with FAP, the risk of desmoid fibromatosis is increased up to 800-fold compared with the general population; cumulative risk of onset fibromatosis is 16% in the 10 years after colectomy (peak incidence in 1 to 3 years following colorectal surgery) [31]. A surgical approach can be justified for the parietal locations followed by drugs or radiotherapy with a low recurrence rate [32].

In patients with intrabdominal tumors, a modulated therapeutic approach (surgery alone or associated with RT, CT), or also an abstentionist behavior can be justified for the unpredictable natural history of this disease, characterized sometimes by spontaneous regressions and absence of growth of tumor for a long period; even though it has been reported that these lesions have an higher rate of recurrence when associated with FAP [33].

The role of radiotherapy (RT) is yet not clear. Several studies reported the RT efficacy (partial or complete tumoral regression), using 50–60 Gy, with a local control in 89% and recurrences in 20% to 30% [34-35]. Successes could depend on menopausal induction and the consequential estrogenic decrease in women. This hypothesis is also supported by the low radiosensitivity observed in men.

In our study, we observed only 5 patients with FAP and DT among the 45 FAP patients enrolled. In all parietal tumors, a wide exeresis was possible with safe margins and a minimal rate of recurrence. The surgical treatment of desmoids offers some considerations about the possibility of aggressive procedures and the extension of exeresis, when feasible (Figure 1). The biological characteristics of desmoids do not always allow a perfect exeresis because the nearest structures can be strongly infiltrated at the

![Table 1: Demographic and clinical presentation of the 5 patients with FAP and desmoid tumor](image)

| PATIENTS’ CHARACTERISTICS | N* |
|---------------------------|----|
| AGE (years)               | 25-65 |
| GENDER                    |     |
| Female                    | 5   |
| Male                      | 0   |
| PREVIOUS SURGERY          |     |
| Total colectomy with ileo-rectal anastomosis (IRA) | 1 |
| Proctocolectomy with ileo-anal anastomosis (IPAA) | 4 |
| CLINICAL PRESENTATION     |     |
| Rectus Abdominis          | 2   |
| Palpable mass             | 2   |
| Subocclusion and abdominal pain | 0 |
| Bleeding                  | 0   |
| Hydronephrosis            | 0   |
| External Oblique Muscle   | 2   |
| Palpable mass             | 2   |
| Subocclusion and abdominal pain | 0 |
| Bleeding                  | 1   |
| Hydronephrosis            | 0   |
| Mesentery                 | 1   |
| Palpable mass             | 0   |
| Subocclusion and abdominal pain | 0 |
| Bleeding                  | 1   |
| Hydronephrosis            | 1   |

![Table 2: Therapeutic choices](image)

| PARIETAL LOCALIZATION, N: |
|---------------------------|
| Surgery (wide excision)   | 4   |
| Radiotherapy after surgery| 1   |
| Adjuvant Chemotherapy     |     |
| (sulindac and tamoxifene) | 1   |
| MESENTERIC LOCALIZATION, N: |
| Chemotherapy (sulindac and tamoxifene) | 1 |
| Chemotherapy (with doxorubicine and dacarbazine) | 1 |

4 Conclusion

The DT represents an unfortunate event for patient with FAP and is the third most frequent cause of death in this patient setting. The management of DT is not yet standardized, and it can be different in case of parietal or intra-abdominal locations. Our experience shows how the treatment of these tumors might be particularly challenging. In patients with FAP, the risk of desmoid fibromatosis is increased up to 800-fold compared with the general population; cumulative risk of onset fibromatosis is 16% in the 10 years after colectomy (peak incidence in 1 to 3 years following colorectal surgery) [31]. A surgical approach can be justified for the parietal locations followed by drugs or radiotherapy with a low recurrence rate [32].

In patients with intrabdominal tumors, a modulated therapeutic approach (surgery alone or associated with RT, CT), or also an abstentionist behavior can be justified for the unpredictable natural history of this disease, characterized sometimes by spontaneous regressions and absence of growth of tumor for a long period; even though it has been reported that these lesions have an higher rate of recurrence when associated with FAP [33].

The role of radiotherapy (RT) is yet not clear. Several studies reported the RT efficacy (partial or complete tumoral regression), using 50–60 Gy, with a local control in 89% and recurrences in 20% to 30% [34-35]. Successes could depend on menopausal induction and the consequential estrogenic decrease in women. This hypothesis is also supported by the low radiosensitivity observed in men.

In our study, we observed only 5 patients with FAP and DT among the 45 FAP patients enrolled. In all parietal tumors, a wide exeresis was possible with safe margins and a minimal rate of recurrence. The surgical treatment of desmoids offers some considerations about the possibility of aggressive procedures and the extension of exeresis, when feasible (Figure 1). The biological characteristics of desmoids do not always allow a perfect exeresis because the nearest structures can be strongly infiltrated at the
time of surgery. Thus, it can be necessary to perform a palliative procedure (gastrointestinal bypasses, transuretero-ureterostomy) [36-39].

In conclusion, our experience supports a modulated approach to the single patient, with surgery as treatment of choice for parietal localization and integrating different kinds of therapies for the intra-abdominal ones. We indicate early identification of high-risk subjects, such as young women, who are candidates for a restrictive follow-up and an early colectomy. We urge cooperation with National FAP Registers [40].

Abbreviations

FAP: familial adenomatous polyposis
DT: desmoid tumor
MAP: MUTYH-associated polyposis
FNC: Fine-Needle Cytology

Competing Interest: The authors declare that they have no competing interests.

Funding Statement: No funding was received

Authors’ contributions: AC, CS, and NC equally contributed to this work, designed the study, and wrote the manuscript. All authors were involved in the study’s concept, data analysis of the manuscript, and the critical revision of the manuscript for important intellectual content. All authors revised and approved the final version of the article.

References

[1] Mueller J, Ueber den feinern bau und formen der Krankhaften geschwulsta, Berlin: G Reimer and Erste Lieferung, 1838: 60
[2] Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009 Oct 12;4:22. doi: 10.1186/1750-1172-4-22
[3] Sturt NJ, Clark SK. Current ideas in desmoid tumours. Fam Cancer. 2006;5(3):275-85; discussion 287-288
[4] Thirlwell C, Howarth KM, Segditsas S, Guerra G, Thomas HJ, Phillips RK, et al. Investigation of pathogenic mechanisms in multiple colorectal adenoma patients without germline APC or MYH/MUTYH mutations. Br J Cancer 2007;96(11):1729-34. DOI: 10.1038/sj.bjc.6603789
[5] Peluso G, Incollingo P, Calogero A, Tammaro V, Rupealata N, Chiachio G, et al. Current tissue molecular markers in colorectal cancer: A literature review. Biomed Res Int. 2017;2017:2605628. doi: 10.1155/2017/2605628
[6] Truta B, Allen BA, Conrad PG, Weinberg V, Miller GA, Pomponio R, et al. A comparison of the phenotype and genotype in adenomatous polyposis patients with and without a family history, Fam Cancer. 2005, 4, (2), 127-33, DOI: 10.1007/s10689-004-5814-0
[7] Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetration, and mutation rate. Hum. Mutat. 1994; 3: 121-125
[8] Carlomagno N, Santangelo ML Mastromarino R, Calogero A, Dodaro C, Renda A. Rare multiple primary malignancies among surgical patients-a single surgical unit experience. Ecancermedicalscience. 2014; 8: 438.
[9] Roncucci L, Pedroni M, Mariani F. Attenuated adenomatous polyposis of the large bowel: Present and future. World J Gastroenterol. 2017;23(23):4135-4139. doi: 10.3748/wjg.v23.i123.4135
[10] Santangelo ML, Grifasi C, Criscitiello C, Giuliano M, Calogero A, Dodaro C, et al. Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. Aging Clin Exp Res, 2017, 29, (Suppl 1), 73-78, doi: 10.1007/s40520-016-0656-9
[11] Grifasi C, Calogero A, Esposito A, Dodaro C. Perioperative care of elderly outpatient: a review. Ann Ital Chir. 2015;86(2):100-105
[12] Desurmont T, Lefevre JH, Shields C, Colas C, Tiret E, Park Y. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer, 2015, 14, (3), 31-39
[13] Chittleborough T, Warrier SK, Heriot AG, Kalady M, Church J. Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ J Surg. 2017 Jun;87(6):441-445. doi: 10.1111/ans.13919
[14] Shapovalov G, Skryma R, Prevorskaya N. Calcium channels and prostate cancer. Recent Pat. Anticancer Drug. Discov, 2013,8,(1),18e26.11
[15] Moccia F, Zuccolo E, Poletto V, Turin I, Guerra G, Pedrazzoli P, et al. Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. Curr Med Chem. 2016, 23,(30), 3450-3480, DOI: 10.2174/0929867323666160607111220
[16] Dragoni S, Laforenza U, Bonetti E, Reforgiato M, Poletto V, Lodola F, et al. Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis. PLoS One 2014,9,(3),e91099, doi: 10.1371/journal.pone.0042541
[17] Dragoni S, Turin I, Laforenza U, Potenza DM, Bottino C, Glasonov TN, et al. Store-operated ca(2+) entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma. Biomed Res Int, 2014,2014,739494, doi: 10.1155/2014/739494
[18] Lodola F, Laforenza U, Bonetti E, Lim D, Dragoni S, Bottino C, et al. Store operated Ca2+ entry is remodelled and controls in vivo angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One 2012,7,(9),e90641
[19] Moccia F, Dragoni S, Lodola F, Bonetti E, Bottino C, Guerra G et al. Store-dependent Ca2+ entry in endothelial progenitor cells as a perspective tool to enhance cell based therapy and adverse tumour vascularization. Curr Med Chem. 2012, 19,(12), 15802-5818, DOI: 10.2174/092986712804143240
[20] Moccia F, Lodola F, Dragoni S, Bonetti E, Bottino C, Guerra G, et al. Ca2+ Signalling in endothelial pro genitor cells: a novel Management of desmoid tumor bleeding
means to improve cell-based therapy and impair tumour vascularization, Curr Vasc Pharmacol. 2014, 12, 87-105, DOI: 10.2174/15701611201140327162858

[21] Dragooni S, Reforgiato M, Zuccolo E, Poletto V, Lodola F, Ruffinatti FA et al. Dysregulation of VEGF-induced pro-angiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony forming cells Exp Hematol. 2015 Dec;43(12):1019-1030.e3. doi: 10.1016/j.exphem.2015.09.002. PMID: 26432919

[22] Zuccolo E, Bottino C, Diofano F, Poletto V, Codazzi AC, Mannarino S et al. Constitutive store-operated Ca2+ entry leads to enhanced nitric oxide production and proliferation in infantile hemangioma-derived endothelial colony forming cells. Stem Cells Dev, 2016, 25, (4), 301-19, doi: 10.1089/scd.2015.0240

[23] Poletto V, Dragoni S, Lim D, et al. Endoplasmic Reticulum Ca2+ Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. J Cell Biochem, 2016, 117, (10), 2260-71, doi: 10.1002/jcb.2015.0240

[24] Moccia F, Zuccolo E, Poletto V, Cinelli M, Bonetti E, Guerra G, et al. Endothelial progenitor cells support tumour growth and metastatization: implications for the resistance to anti-angiogenic therapy. Tumour Biol, 2015, 36, (9), 6603-14. doi: 10.1007/s13277-015-3823-2

[25] Moccia F, Guerra G. Ca2+ Signalling in Endothelial Progenitor Cells: Friend or Foe? J Cell Physiol, 2016, 231, (2), 314-27. doi: 10.1002/jcp.25126

[26] Potenza DM, Guerra G, Avanzato D, Poletto V, Pareek S, Guido D et al. Hydrogen sulphide triggers VEGF-induced intracellular Ca2+ signals in human endothelial cells but not in their immature progenitors. Cell Calcium, 2014,56,(3),225-34. doi: 10.1016/j.ceca.2014.07.010

[27] Ronco V, Potenza DM, Denti F, Vullo S, Gagliano G, Tognolina M et al. A novel Ca2+-mediated cross-talk between endoplasmic reticulum and acidic organelles: implications for NAADP-dependent Ca2+ signaling, Cell Calcium. 2015,57,(2),89-100, doi: 10.1016/j.ceca.2015.01.001

[28] Zuccolo E, Dragoni S, Poletto V, Catarsi P, Guido D, Rappa A, et al. Arachidonic acid-evoked Ca2+ signals promote nitric oxide release and proliferation in human endothelial colony forming cells. Vascul Pharmacol, 2016, 87, 159-171.doi: 10.1016/j.vph.2016.09.005

[29] Rippa E, Altieri F, Di Stadio CS, Miselli G, Lamberti A, Federico A et al. Ectopic expression of gastrin-1 in gastric cancer cells up-regulates tight and adherens junction proteins network. Pathol Res Pract. 2015, 211, (8), 577-83, doi: 10.1016/j.prp.2015.04.008

[30] Di Nezza F, Zuccolo E, Poletto V, Rosti V, De Luca A, Moccia F, et al. Liposomes as a Putative Tool to Investigate NAADP Signaling in Vasculogenesis. J Cell Biochem. 2017. doi: 10.1002/jcb.26019

[31] Righetti AEM, Jacomini C, Parra RS, Almeida ALNRd, Rocha JFR, Feres O. Familial adenomatous polyposis and desmoid tumors. Clinics. 2011;66(10): 1839-1842

[32] Chittleborough TJ, Warrier SK, Heriot AG, Kalady M, Church J. Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ J Surg. 2017 Jun;87(6):441-445. doi: 10.1111/ans.13919

[33] Dinarvand P, Davaro EP, Doan JV, Ising ME, Evans NR, Phillips NJ, et al. Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations. Arch Pathol Lab Med. 2019 May 9. doi:10.5858/arpa.2018-0570-RA

[34] Gaggelli I, Scipioni F, Tirone A, Carli AF. Intra-abdominal desmoid tumors: a case report. Ann Ital Chir. 2014 Oct 7;85(ePub). pii: S2239253X14023056. PMID: 25335448

[35] Mussi CE, Colombo P, Lo Russo C, Kasangian A, Cananzi F, Marrari A, et al. Sporadic desmoid tumors of the abdominal wall: the results of surgery. Tumori, 2016;102(6),582-587. doi: 10.5301/tj.5000552

[36] Carlomagn N, Santangelo ML, Amato B, Calogero A, Saracco M, Cremone C, et al., Total colectomy for cancer, analysis of factors linked to patients’ age. International Journal of Surgery 2014, 12 (52), S135-139

[37] Santangelo ML, Criscitiello C, Renda A, Federico S, Curigliano G, Dodaro C, et al. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. Biomed Res Int. 2015;2015:183523.  doi: 10.1155/2015/183523. PMID: 26185750

[38] Koskenvuo, L, Pitkaniemi, J, Rantanen, M, Lepisto, A. Impact of screening on survival in familial adenomatous polyposis. J. Clin. Gastroenterol. 2016; 50: 40-44

[39] Lasseur A, Pasquer A, Feugier P, Poncet G. Sporadic intra-abdominal desmoid tumor: a unusual presentation. J Surg Case Rep. 2016, 2016(5), rjw070

[40] Vasen, HFA, Möslin G, Alonso A, Aretz S, Bernstein I, Bertario L A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57: 704-713